Investment
Features
FeesSafety
Academy
More
Pluang+

Dimensional Fund Advisors discloses 1.66% stake in SThree PLC shares as of October 2026

Market News
14 Oct 2026
Globe News Wire
View Source
Neutral
Dimensional Fund Advisors discloses 1.66% stake in SThree PLC shares as of October 2026

Dimensional Fund Advisors Ltd. has disclosed an ownership of 2,022,423 shares, representing 1.66% of the ordinary shares in SThree PLC as of October 13, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicating Dimensional's significant investment interest in the company. The firm also reported recent purchases and a transfer of shares, but no derivative dealings or special agreements related to voting rights or options. This stake signals Dimensional's continued involvement in SThree PLC's equity, which may influence future shareholder dynamics.

Dimensional Fund Advisors Ltd.'s ownership disclosure in SThree PLC provides context for readers. For those tracking Industrials-sector stocks on Pluang, 89 out of 136 stocks rose and 41 fell as of Oct 14, 2026 17:01 WIB. Notable prices include CXW at USD 33.50 with a -1.56% change, DHT at USD 27.00 with a +1.54% change and a typical hold time of 1 day, and SUNB at USD 78.41 with a +1.40% change and a typical hold time of 5 days.

More News

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall raises $4M to launch AI-driven autonomous attack agents for continuous enterprise security testing.

CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...

Others
Bullish
1 hour ago
Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics names John O’Malley as Chief Medical Officer to advance autoimmune drug pipeline.

Matchpoint Therapeutics has appointed John O’Malley, M.D., Ph.D., as its Chief Medical Officer. Dr. O’Malley brings extensive experience in immunology and clinical development from his previous roles at CRISPR Therapeutics and Sanofi. His leadership ...

Market News
Bullish
2 hours ago
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome

Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...

Market News
Bullish
2 hours ago
DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global to release Q3 2026 financial results on October 27 after market close

DMC Global Inc. will announce its financial results for the third quarter ending September 30, 2026, on October 27 after the stock market closes. The company will hold a conference call and webcast to discuss the results, providing investors with ins...

Company Fundamentals
Neutral
2 hours ago
Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware launches MCP Server Protection to secure AI integration layers from attacks and abuse.

Radware introduced its Model Context Protocol (MCP) Server Protection solution to help organizations secure the integration layer where AI agents connect to enterprise applications and workflows. This new security tool provides visibility into MCP in...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App